Urgent.News

What's breaking now, across thousands of outlets.

More in Business

Celltrion Extends Biosimilar Lead Across Asia

Celltrion is solidifying its dominance in the Asian region, a representative pharmerging (emerging pharmaceutical) market, driven by the overwhelming market share of its flagship product lineup for…

  • Celltrion maintains 95% market share in Singapore for autoimmune treatment Remsima.
  • Herzuma ranks first in Hong Kong, Thailand, and Malaysia for breast and gastric cancer.
  • Truxima secures 92% market share in Singapore for blood cancer treatment.

More from Thursday 19 November →